drugset / Trial / NCT00367315

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)

NCT00367315

Phase 3 Completed 1684 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis (OA)

Timeline

Start
2003-09
Primary completion
2004-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumiracoxib Small molecule 100 mg

Indications